Akari Therapeutics Plc
Nasdaq · Healthcare · Pharmaceutical Preparations · Tampa, FL
AKTX chart
What traders are saying about $AKTX
Latest postsAkari Therapeutics Plc news
- Akari Therapeutics Plc Estimates – NASDAQ:AKTX
TradingView ·
- Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Yahoo Finance ·
- Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Yahoo Finance ·
- Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Yahoo Finance ·
- Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Yahoo Finance ·
- Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Yahoo Finance ·
- Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Yahoo Finance ·
- Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
Yahoo Finance ·
- Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Yahoo Finance ·
- Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
Yahoo Finance ·
- Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Yahoo Finance ·
- Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board
Yahoo Finance ·
Akari Therapeutics Plc key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $367,877 | $607,681 |
| Net income | -$17.3M | -$19.8M | -$10.0M | -$13.1M |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $-0.74 |
| Total assets (year end) | $47.9M | $50.6M | $4.4M | $7.5M |
| Cash and equivalents (year end) | $5.2M | $0 | $3.8M | $654,892 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Akari Therapeutics Plc
- Ticker
- AKTX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Tampa, FL
- Incorporated in
- United Kingdom
- Fiscal year end
- December 31
- SEC CIK
- 1541157
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
Frequently asked questions
What exchange is Akari Therapeutics Plc listed on?
Akari Therapeutics Plc trades on the Nasdaq under the ticker symbol AKTX.
What industry is Akari Therapeutics Plc in?
Akari Therapeutics Plc is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Akari Therapeutics Plc headquartered?
Akari Therapeutics Plc's business address on file with the SEC is in Tampa, FL.
When does Akari Therapeutics Plc's fiscal year end?
Akari Therapeutics Plc's fiscal year ends on December 31.
How much revenue did Akari Therapeutics Plc report?
Akari Therapeutics Plc reported $367,877 in revenue for calendar year 2023, according to its SEC filings.